5 Best Day Trading Stocks to Buy Now

Published on March 13, 2026 at 6:35 am by Ramish Cheema in News

In this article, we will discuss: 5 Best Day Trading Stocks to Buy Now. For more stocks, you can head to 11 Best Day Trading Stocks to Buy Now.

5. Hims & Hers Health, Inc. (NYSE:HIMS)

Number of Hedge Fund Holdings: 39

Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)’s shares on March 11th. It raised the share price target to $29 from $25 and kept an Overweight rating on the stock. Barclays commented that the fact that Hims & Hers Health, Inc. (NYSE:HIMS)’s shares had performed well after its agreement with Novo Nordisk indicated that the firm’s legal woes were behind it. Barclays added that the market appeared to be underestimating the opportunities for new products from new products.

Barclays coverage came after Novo Nordisk announced that it had decided to drop its legal action against Hims & Hers Health, Inc. (NYSE:HIMS) for what the healthcare company dubbed an illegal compound dispute. Novo had taken the action after Hims & Hers Health, Inc. (NYSE:HIMS) had announced that it would sell its own weight loss pill. The development came after the pair had ended their partnership last year to provide discounted weight loss shots to Hims & Hers Health, Inc. (NYSE:HIMS)’s customers.

Hims & Hers Health, Inc. (NYSE:HIMS) is a health platform that offers prescription and non-prescription products to consumers. The firm is headquartered in San Francisco, California.

4. Figure Technology Solutions, Inc. (NASDAQ:FIGR)

Number of Hedge Fund Holdings: 40

Financial firm Mizuho discussed technology company Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s shares on March 10th. It lowered the share price target to $55 from $64 and kept an Outperform rating on the stock. As part of its coverage, the financial firm outlined that it continued to be optimistic about Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s long term growth potential. The technology firm partnered up with BitGo Holdings in February to complete the world’s first fully on-chain equity trades through which shares were issued, traded, and settled through blockchain technology.

Investment firm Piper Sandler discussed Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s shares in January. It raised the price target to $75 from $55 and kept an Overweight rating on the stock. The coverage came after the technology company reported its earnings for the fourth quarter of 2025. The results saw Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s total client loans jump to $2.7 billion from $1.17 billion from the year-ago quarter.

Figure Technology Solutions, Inc. (NASDAQ:FIGR) is a technology company that provides a blockchain-based market platform for trading and investing. It is headquartered in Reno, Nevada.

3. Dyne Therapeutics Inc. (NASDAQ:DYN)

Number of Hedge Fund Holdings: 61

Earlier this month, Dyne Therapeutics Inc. (NASDAQ:DYN) announced important updates for its DMD and DM1 programs. The firm revealed that it planned to submit an accelerated application for its DMD drug to target a launch in the first quarter of 2027. Dyne Therapeutics Inc. (NASDAQ:DYN) added that for DM1, it had completed enrollment for a Phase 1/2 trial. On March 8th, the firm revealed that it had started a Phase 3 trial of the drug DYNE-101 for the disease, and on the same day, Dyne Therapeutics Inc. (NASDAQ:DYN) revealed that its Phase 1/2 DELIVER trial for DMD had shown results when it came to baseline in lung function and other metrics.

Investment bank Morgan Stanley discussed the pharmaceutical company’s shares on March 3rd. It reduced the share price target to $47 from $50 and kept an Overweight rating, according to The Fly. Morgan Stanley outlined that Dyne Therapeutics Inc. (NASDAQ:DYN)’s programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) were on track, and 2026 could see the firm execute on its key programs.

Dyne Therapeutics Inc. (NASDAQ:DYN) is a biotechnology company focusing on developing treatments for neuromuscular diseases. It is headquartered in Waltham, Massachusetts.

2. Mineralys Therapeutics Inc. (NASDAQ:MLYS)

Number of Hedge Fund Holdings: 88

Biopharmaceutical company Mineralys Therapeutics Inc. (NASDAQ:MLYS) scored a win on March 9th when it announced that the Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for its lorundrostat drug to treat hypertension when combined with other hypertensive drugs. As part of the release, the firm’s CEO outlined that while the drug’s Explore-OSA trial did not show a reduction in the apnea-hypopnea index (AHI), the drug’s safety profile and its impact on blood pressure were nevertheless meaningful.

The FDA’s NDA approval came after Mineralys Therapeutics Inc. (NASDAQ:MLYS) announced in January that it had submitted the application. In December 2025, Bank of America raised the firm’s share price target to $46 from $43 and kept a Buy rating on the stock. The coverage came after Mineralys Therapeutics Inc. (NASDAQ:MLYS)’s earnings report for the third quarter of 2025, which saw the firm confirm that it had a cash runway up to 2027.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is a biotechnology company that is focused on developing drugs for ailments stemming from aldosterone dysregulation. It is headquartered in Radnor, Pennsylvania.

1. Lumentum Holdings Inc. (NASDAQ:LITE)

Number of Hedge Fund Holdings: 97

Investment bank Barclays discussed photonics and optical products manufacturer Lumentum Holdings Inc. (NASDAQ:LITE)’s shares on March 3rd. It raised the share price target to $750 from $475 and kept an Equal-Weight rating on the shares. The coverage came a month after Lumentum Holdings Inc. (NASDAQ:LITE) reported its earnings for the second fiscal quarter of 2026. The results saw the firm report $665 million in revenue and $143 million in non-GAAP net income.

On the same day, Rosenblatt also discussed Lumentum Holdings Inc. (NASDAQ:LITE)’s shares. It raised the share price target to $900 from $580 and kept a Buy rating on the stock. Rosenblatt pointed out that the firm will benefit from AI chip giant NVIDIA’s decision to invest $2 billion in it and to secure future capacity for optical products. Like the two financial firms, investment bank Morgan Stanley is also optimistic about Lumentum Holdings Inc. (NASDAQ:LITE). It raised the price target to $520 from $420 and kept an Equal Weight rating on the shares.

Lumentum Holdings Inc. (NASDAQ:LITE) is an American company that makes and sells optical and photonic products used in computing and other applications. It is headquartered in San Jose, California.

While we acknowledge the potential of LITE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LITE and that has 100x upside potential, check out our report about this cheapest AI stock.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

NYSE:HIMS NASDAQ:DYN NASDAQ:FIGR NASDAQ:LITE NASDAQ:MLYS Show more...

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Insider Monkey Ads

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returns! Sign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on this $3 stock with 400% upside potential.
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

5 Best Day Trading Stocks to Buy Now

Published on March 13, 2026 at 6:35 am by Ramish Cheema in News

5. Hims & Hers Health, Inc. (NYSE:HIMS)

4. Figure Technology Solutions, Inc. (NASDAQ:FIGR)

3. Dyne Therapeutics Inc. (NASDAQ:DYN)

2. Mineralys Therapeutics Inc. (NASDAQ:MLYS)

1. Lumentum Holdings Inc. (NASDAQ:LITE)

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

5 Best Day Trading Stocks to Buy Now

Published on March 13, 2026 at 6:35 am by Ramish Cheema in News

Share

5. Hims & Hers Health, Inc. (NYSE:HIMS)

4. Figure Technology Solutions, Inc. (NASDAQ:FIGR)

3. Dyne Therapeutics Inc. (NASDAQ:DYN)

2. Mineralys Therapeutics Inc. (NASDAQ:MLYS)

1. Lumentum Holdings Inc. (NASDAQ:LITE)

Subscribe to Insider Monkey's Free Daily Newsletter and Join 80K+ Readers

Share

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up: